IPO
Experts are predicting a record-breaking rush of IPOs this fall as companies flood to the Nasdaq.
Tyra Biosciences aspires to raise a $100 million IPO, according to its S-1 form filed with the U.S. Securities and Exchange commission late last week.
The global biopharmaceutical company said that it is well capitalized with cash, cash equivalents, restricted cash, and investments of as much as $222.8 million as of 30 June 2021.
Show me the money! This week’s who’s who of IPOs and financing rounds in the biopharma world.
Shares of Zymergen plummeted by 68% Tuesday from its April IPO price of $31 per share to just $11.7 per share after news that the company will not likely see revenue anytime soon.
It is offering 17.7 million shares with an expected price between $16 and $18 per share. It will trade on the Nasdaq under the ADGI ticker symbol.
The U.S. Securities and Exchange Commission has halted registrations of U.S. initial public offerings (IPOs) by Chinese companies.
Nuvalent, Rallybio and Icosavax all began selling on the Nasdaq Exchange today.
Deerfield Management and ARCH Venture Partners have partnered with venture capital firm Section 32 to sponsor DA32 Life Science Tech Acquisition Corp, a blank check company that is today priced for $200 million in an initial public offering (IPO).
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
PRESS RELEASES